Why is ipamorelin stacked with CJC-1295?

The Two-Pathway Advantage

Your pituitary releases growth hormone in response to signals from two different hormones:

• GHRH (growth hormone releasing hormone) — primary driver of GH release
• Ghrelin — amplifies GHRH signaling through a separate receptor

Using only one signal limits the achievable pulse size. Combining both mimics how your pituitary actually operates during a natural GH pulse, when both hormones rise together.

CJC-1295 Activates the GHRH Pathway

• GHRH analog with a drug affinity complex (DAC) version that extends half-life dramatically
• Binds GHRH receptors on the pituitary
• Triggers GH release through adenylate cyclase/cAMP pathway

Ipamorelin Activates the Ghrelin Pathway

• Ghrelin receptor (GHSR-1a) agonist
• Much more selective than older GHRPs — minimal cortisol or prolactin spillover
• Triggers GH release through phospholipase C pathway

What the Combination Produces

When you inject both at bedtime:

• CJC-1295 provides sustained elevation of GHRH signal
• Ipamorelin adds a ghrelin-pathway amplification
• Combined GH pulse is larger and longer than either alone
• The pulse coincides with natural sleep-driven GH release

CJC-1295 With or Without DAC

Two versions of CJC-1295 exist:

CJC-1295 with DAC (Long-Acting)

• Drug affinity complex extends half-life to ~8 days
• Produces steady GH elevation rather than pulses
• Less commonly used in modern protocols because continuous elevation lacks the physiologic pulsatile pattern

CJC-1295 without DAC (Short-Acting, Mod GRF 1-29)

• Half-life ~30 minutes
• Produces acute pulses matching ipamorelin's timing
• Standard for anti-aging and recovery protocols
• Allows pulsatile GH release that mimics natural rhythm

Most current protocols use CJC-1295 without DAC specifically to preserve pulsatile release.

Typical Dosing

• CJC-1295 (no DAC): 100–300 mcg subcutaneously
• Ipamorelin: 100–300 mcg subcutaneously
• Timing: Bedtime, 5 nights per week, empty stomach
• Cycle: 12 weeks with 4-week break

The two peptides are often compounded into a single vial ("CJC-1295/Ipamorelin blend") so a single injection delivers both.

Expected Effects Over 12 Weeks

• Weeks 1–2: Often vivid dreams, possibly some water retention
• Weeks 3–4: Improved sleep quality, recovery from training
• Weeks 4–8: Subtle body-composition changes — fat reduction, slight lean mass gain
• Weeks 8–12: Better skin quality, ongoing recovery benefit, stable appetite effects

Stacking With BPC-157

CJC-1295 + ipamorelin + BPC-157 is a common triple stack for patients with recovery or injury focus. See our BPC-157 + ipamorelin stack guide for details.

Side Effects of the Combination

• Water retention (usually resolves in 1–2 weeks)
• Tingling or numbness in hands/feet (transient, rare)
• Vivid dreams
• Mild appetite increase (more from ipamorelin's ghrelin pathway than CJC-1295)
• Injection-site reactions
• Slight blood sugar elevation — monitor if diabetic

Who Should Avoid the Stack

• Active malignancy or recent cancer (GH-stimulating protocols are avoided)
• Uncontrolled diabetes
• Pregnancy or breastfeeding
• Competitive athletes under WADA — both peptides are prohibited
• Active proliferative retinopathy

See ipamorelin, CJC-1295, and BPC-157 + ipamorelin stack.